PDS Biotech Reports Third Quarter 2022 Financial Results
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV)...
United States University Of Texas Frank Bedu Matthew Hill National Cancer Institute University Of Texas Md Anderson Cancer Center
Source: globenewswire.com